Anova Enterprises, a technology-driven contract research organization, has unveiled a groundbreaking AI-enabled patient matching solution designed to accelerate clinical trial enrollment worldwide.

The platform, part of Anova’s global just-in-time research network, connects patients with open clinical trials and investigational products for compassionate use.

Available at no cost to participating research sites, the solution leverages AI and proprietary algorithms to pinpoint patients who meet trial eligibility criteria with exceptional accuracy. It cross-references demographic, molecular, and clinical history data against more than 200,000 ongoing trials.

Clinical trial enrollment has long been a bottleneck in drug development, with nearly 80% of studies delayed by recruitment challenges. Anova’s new platform addresses this by providing research teams a seamless, easy-to-use tool that integrates directly into existing clinical workflows, streamlining patient screening.

The AnovaOS SaaS platform connects sponsors to over 60,000 research-ready clinical sites globally, allowing sites to identify trial opportunities for their patients and practices efficiently. Key features include automated eligibility screening, secure data handling, real-time trial updates, and scalable access for sites ranging from large academic centers to community practices.

“By making this solution free to access, we are empowering research sites of all sizes to connect the right patients with the right studies when treatment decisions are being made,” said Christopher Beardmore, CEO and Co-founder of Anova.

“The only way to present clinical trial options to patients is when the decision to select the next line of therapy is being made. That cannot be done when study teams rely on medical record review, pathology results and potential patient lists. Patients are lost to study (and lose access to promising new treatments) when that approach is used.

"The AnovaOS solution not only provides a study matching capability, but supports a global just-in-time network to enable access to any investigational product just-in-time, either through a clinical trial or compassionate use.”

By eliminating cost barriers, Anova aims to expand access to advanced technology, foster inclusive research participation, help sponsors meet enrollment goals, and accelerate delivery of promising therapies to patients in need.